Decoding Immunity
Encoding the Future

BayVax Biotech leverages proprietary deep learning frameworks to simulate complex immune interactions, enabling the rapid design and validation of novel antigens for next-generation personalised and broad-spectrum vaccines.

Explore Platform Clinical Pipelines

AI-Powered Platform

Our computational platform models molecular interactions involved in immune recognition, supporting neoantigen selection and therapeutic design.

Immune Discriminator

Fusion-pM and Fusion-pMT model peptide–HLA binding and TCR recognition to support neoantigen prioritisation.

View Webserver

Immune Generator

Enables de novo design of T-cell receptor (TCR) sequences engineered for high-affinity binding.

Immune Toolbox

An integrated suite for the entire computational workflow, from in-silico HLA genotyping to generative design.

Immune modelling & design

AIVIS

AI Virtual Immune System

AIVIS is BayVax's framework for building computational models of immune recognition and responses to support vaccine and immunotherapy research. It combines immune data and biological knowledge with protein language models, physicochemical features and cross-attention.

B-cell & antibody recognition

Linear and conformational epitope prediction helps assess antibody binding sites and viral mutations, supporting antigen evaluation and broad-spectrum vaccine design.

T-cell presentation & recognition

Peptide–HLA binding and peptide–HLA–TCR recognition models support epitope selection and personalised neoantigen design, including the BXP-001 workflow.

Prediction, validation and candidate selection

  1. Research inputsAntigen sequences, structures and HLA information
  2. AI assessmentComplementary B-cell and T-cell scores
  3. Functional validationAntigen-specific antibody and T-cell evaluation
  4. Candidate decisionsEvidence-based ranking, coverage assessment and next experiments

Experimental, manufacturing and clinical evidence feeds back into model improvement. Predictions guide candidate selection; functional testing establishes the evidence for each project.

Research tools and therapeutic programmes

AIVIS supports software services and model licensing, task-specific co-development, and the development or licensing of vaccine and immunotherapy candidates.

Discuss a collaboration →

Precision Immunotherapy

We are translating computational insights into a new generation of tangible therapeutic strategies for oncology and infectious diseases.

Digital Pipelines

Deploying our validated computational pipelines through strategic licensing and co-development partnerships.

Personalised Vaccines

Developing patient-specific neoantigen vaccines for solid tumors, demonstrating significant PFS extension.

Broad-Spectrum

Designing novel antigens that elicit broad-spectrum, cross-reactive immune responses to diverse pathogens.

AI Neoantigen Discovery

Two biological steps.
Two complementary AI models.

Peptide binding to HLA precedes recognition by a T-cell receptor. Our sequence-fusion models follow this biological order to help prioritise patient-specific neoantigen candidates.

01 / ANTIGEN PRESENTATION

Fusion-pM

Can the peptide bind to the patient's HLA?

Peptide8–14 amino acids HLA pseudosequence34 amino acids

Cross-attention learns interactions between peptide and HLA residues. Padding-aware positional encoding and masking preserve sequence information across different peptide lengths.

Output: peptide–HLA binding probability (0–1)

02 / TCR RECOGNITION

Fusion-pMT

Can a specific TCR recognise the pMHC?

Peptide + HLApMHC features TCR CDR3βWhen available

Shared amino-acid encoding and sequential cross-attention fuse all three sequences. Peptide–MHC pretraining supports subsequent fine-tuning on peptide–MHC–TCR binding data.

Output: TCR-specific triad binding score

Without TCR data, candidates can be prioritised using peptide–HLA binding and expression. Binding is one component of antigen presentation; these scores support selection and do not by themselves establish T-cell activation or clinical efficacy.

Fusion-pM · Held-out binding test

0.9789ROC-AUC
0.9692PR-AUC
0.9330Accuracy

515,149 training pairs; 82,112 held-out test pairs. ROC-AUC ≥0.90 across all 112 evaluated HLA alleles.

Fusion-pMT · Generalisation tests

Fusion-pMT ROC-AUC and accuracy on two generalisation test sets
Test setROC-AUCACC
Unseen peptide0.73260.7092
Out of distribution0.63200.6001

AI prioritisation in the BXP-001 workflow

BXP-001 workflow: patient samples, sequencing, AI prioritisation, peptide synthesis and vaccine administration
  1. Patient samplesTumour tissue and matched normal blood
  2. SequencingWES / WGS and RNA-seq to identify expressed mutations
  3. AI prioritisationBinding and expression; TCR recognition when available
  4. Peptide synthesisPersonalised candidates selected for manufacture
  5. AdministrationInvestigational vaccination under a clinical protocol

Computational evidence and clinical trial outcomes address different questions. BXP-001 clinical research is presented in Events.

Discuss research & pipeline collaboration →

Clinical Pipelines

Our research is advancing through preclinical and clinical stages, validating the power of our AI-driven approach.

Pipeline Portfolio

Candidates Vaccines Modality In-Silico Preclinical Clinical
BXP-001 Neoantigen Cancer Vaccine Peptide IIT
BVX-COV Pan-Coronavirus Vaccine Viral Vector
BVX-AGE Senolytic (Anti-Aging) Vaccine Protein
BVX-AID Autoimmune Disease Vaccine Peptide

Clinical Milestones

2026

iNATURE Results Presented at ESMO 2026

Updated results of the randomised phase II iNATURE trial were presented at ESMO Congress 2026 (LBA52 and 2005P). View event & posters →

2025

IND Application Initiation

The regulatory pathway is opened for neoantigen vaccines, paving the way for our Investigational New Drug application.

2024

Randomised IIT Launched

The randomised IIT (iNATURE) at HKU-Shenzhen Hospital has started.

2023

Randomised IIT Approved

An investigator-initiated trial Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) at The University of Hong Kong-Shenzhen Hospital has been approved by Institutional Review Board.

Prior 2022

Single-Arm IIT

Previous Investigator-Initiated Trials in solid tumours (HCC, MSS-CRC) showed significantly extended Progression-Free Survival (PFS).

Events

Events in 20261 event
2026 · PRESENTED

ESMO Congress 2026

– · Madrid, Spain

Congress website ↗

Two results from the randomised phase II iNATURE study (GCOG0028) were presented at ESMO Congress 2026, covering personalised neoantigen vaccination with critical lesion radiotherapy (CLERT), including interim efficacy and the relationship between radiation exposure and immune preservation.

LBA52 · BXP-001 / iNATURE

Personalized Neoantigen Peptide Vaccine with Critical Lesion Radiotherapy in Refractory Solid Tumors

Prespecified interim analysis of the randomised phase II trial: progression-free survival, immune responses and safety.

2005P · BXP-001 / iNATURE

Does Radiation Dose Matter During Combined Immunotherapy with a Neoantigen Vaccine?

Exploratory interim analysis of radiation exposure to immune cells, lymphocyte nadir and clinical outcomes.

Events in 20251 event
2025 · PRESENTED

IASLC World Conference on Lung Cancer

– · Barcelona, Spain

IASLC poster listing ↗
P2.10.14 · BXP-001 / iNATURE

Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE): a Phase II Randomized Study

View abstract ↗

Scientific Validation

Explore our peer-reviewed articles, research preprints and congress presentations.
‡ First author(s) | * Correspondence author(s)

Publications in 20269 works
Personalized Neoantigen Vaccine Combined with Precision Critical Lesion Radiotherapy (CLERT) in Advanced Solid Tumors: Updated Results from the iNATURE Phase II Trial
ZHANG Y‡, HU Y-F‡, LI R‡, GAO Zb‡, DAI W‡, MA Ly, HAN Y, JIANG Xq, LI Bd, YANG Wh, LIU L, QU Yl, WANG Pc, ZHANG Jl, WANG Qc, CAO Ty, CHEN Wq, HUANG Jj, CHEN X, ZHANG Jj, HUANG J-D, ZHOU Cc, FU P, KONG F-M*
Conference New 2026-10-24 ESMO Congress 2026
LBA52 View poster →
Does Radiation Dose Matter During Combined Immunotherapy with Neoantigen Vaccine
ZHANG Y‡, HU Y-F‡, LI R‡, WANG Pc, DAI W, WANG Qc, HAN Y, ZHANG Jl, CHEN Wq, HUANG Jj, WU Yf, CHAO Dd, MA Ly, CHEN X, YANG G, FU P, HUANG J-D, KONG F-M*
Conference New 2026-10-24 ESMO Congress 2026
2005P View poster →
Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy
WU Y-F‡, HU J-C‡, HU Y-F‡*, LI W-J, RONG L, LI R-H, YAO Y, HU L, WANG X-L, ZHANG B-Z, LU Y, CHOW S-F, SU C, YAU T*, CHUNG CY-S*, HUANG J-D*
Journal Paper New 2026-10-02 Adv. Sci.
View Article
Antigenic and genetic analysis of 2025 Chikungunya virus outbreak in China
HU Y-F‡*, MA Jh‡, ZHANG B-Z‡, CHU H*, HUANG J-D*
Journal Paper New 2026-09-09 Innov. Life
View Article
An AI Agent for Immune Receptor Fingerprint-Based Diagnosis of Infection of Unknown Origin
MA Jh, LI Hz, HU Y-F*, HUANG J-D*
Conference New 2026-08-04 ICPR 2026
View Article
ImmunoTrace: A Meta-agent for Immune History Tracking
MA Jh, LI Hz, HU Y-F*, HUANG J-D*
Conference New 2026-08-04 ICPR 2026
View Article
Ab2Nb: A Physics-Guided Framework for Converting Antibodies into Nanobodies
WU Sp, LI Hz, MA Jh, QIAN Jy, LIANG Z, TANG Sq, HU Y-F*, HUANG J-D*
Conference New 2026-08-03 ICPR 2026
View Article
Pretrained models may fail to capture immunological sequences
MA Jh‡, LI Hz‡, HUANG J-D*, HU Y-F*, CHEN Yf*
Journal Paper New 2026-07-20 Commun. Biol.
View Article
TopoBind: Multi-Modal Prediction of Antibody-Antigen Binding Free Energy via Sequence Embeddings and Structural Topology
YU Cy, LI Hz, MA Jh, TANG Sq, HU Y-F*, HUANG J-D*
Conference 2026-05-03 ICASSP 2026
View Article
Publications in 202510 works
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN. 1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1
Shi Jl‡, Zhao Xy‡*, Jin Xh‡, Li Jy‡, Liu Yc‡, Liu H‡, Hu Y-F‡, (…), He Mz*, Sun L*, Wang Pf*, Chu H*
Journal Paper 2025-12-11 Nat. Commun.
View Article
Physicochemically Informed Dual-Conditioned Generative Model of T-Cell Receptor Variable Regions for Cellular Therapy
Ma Jh, Li Hz, HU Y-F*, HUANG J-D*
Preprint 2025-10-07 arXiv
View Preprint
P2.10.14 Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) a Phase II Randomized Study
Zhang Y, HU Y-F*, Li R, Dai W, Wang Q, Chen W, Huang J, Han Y, Zhang J, Zhang F, Cao T, Ma L, Chen X, Su X, Yang G, Fu P, Huag J, Wang J, Cheung K, Poon WS, Kong FM
Conference 2025-10-01 J. Thorac. Oncol.
View Abstract
ABConformer: Physics-inspired Sliding Attention for Antibody-Antigen Interface Prediction
You Z-Y, Ma Jh, Li Hz, HU Y-F*, HUANG J-D*
Preprint 2025-09-27 arXiv
View Preprint
CAME-AB: Cross-Modality Attention with Mixture-of-Experts for Antibody Binding Site Prediction
Li Hz, Ma Jh, Shi Zp, Xiao R, Jin Fm, HU Y-F*, Che Hj*, HUANG J-D*
Preprint 2025-09-10 arXiv
View Preprint
BConformeR: A Conformer Based on Mutual Sampling for Unified Prediction of Continuous and Discontinuous Antibody Binding Sites
You Zy, Ma Jh, Li Hz, HU Y-F*, HUANG J-D*
Preprint 2025-08-16 arXiv
View Preprint
A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028
Zhang Y‡, Hu Y-F‡, Ma L, Wu Y, Chao D, Chen X, Xu Z, Su X, Dai W, Huang J-D, Fu P, Kong F-M (Spring)*
Journal Paper 2025-08-21 Front. Immunol.
View Article
SPRINT for Benchmarking Sequence-based Immunogenicity PRedIction NeTworks
YIN Yj, LI Hz, MA Jh, CHEN Wj, YU Yy, ZHANG Xy, QU Ty, HUANG J-D*, HU Y-F*, CHEN Yf*
Preprint 2025-05-30 ResearchGate
View Preprint
Remodeling peptide-MHC-TCR triad binding as sequence fusion for immunogenicity prediction
MA Jh, LI Hz, HUANG J-D*, HU Y-F*, CHEN Yf*
Preprint 2025-01-03 arXiv
View Preprint
Distinct evolution patterns of influenza viruses and implications for vaccine development
HU Y-F*, ZHANG B-Z, CHU H*, HUANG J-D*
Journal Paper 2025-01-06 Innovation
View Article
Publications in 20242 papers
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3
LIU Yc‡, ZHAO Xy‡, SHI Jl‡, WANG Yj‡, LIU H‡, HU YF‡, (…), HUANG J-D, YUEN K-Y, TO KK-W, CHAN JF-W, ZHANG B-Z*, SUN L*, WANG Pf*, CHU H*
Journal Paper 2024-10-09 Nat. Commun.
View Article
Personalized tumor neoantigen peptide vaccine combined with radiotherapy in the treatment of advanced tumors-phase II randomized group study
ZHANG Y*, LI R, HU YF, DAI W, WANG J, XU ZY, SU Xp, HUANG J-D, KONG FM
Conference 2024-10-01 Int. J. Radiat. Oncol. Biol. Phys.
View Abstract
Publications in 20233 papers
Family-specific training improves linear B cell epitope prediction for emerging viruses
LIU R, HU Y-F, DU J, ZHANG B-Z, YAU T, FAN X*, HUANG J-D*
Journal Paper 2023-09-04 IEEE/ACM Trans. Comput. Biol. Bioinform.
View Article
Rational design of a booster vaccine against COVID-19 based on antigenic distance
HU Y-F, YUEN T T-T, GONG H-R, HU Bj, HU Jc, (…), ZHANG B-Z*, CHU H*, HUANG J-D*
Journal Paper 2023-08-09 Cell Host Microbe
View Article
A Bayesian approach to estimate MHC-peptide binding threshold
LIU R, HU Y-F, HUANG J-D*, FAN X*
Journal Paper 2023-06-02 Brief. Bioinform.
View Article

Tender Records

Transparent records of our procurement and vendor partnerships.

Results Release: Preclinical Toxicity Study
Project Title Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine
Reference No TOX-2025-001
Budget Not exceeding HKD 1,500,000
Deadline June 6, 2025

1. Tender Progress

The tender announcement was officially released on May 14, 2025. By the deadline of June 6, 2025, bid documents from three qualified vendors were received and shortlisted for in-depth evaluation. As of June 13, 2025 the results of this tender has been released.

2. Tender Results

Pharmaron Beijing Co., Ltd. is recommended as the preferred partner for this project.

Rank Vendors Score
1

Pharmaron Beijing Co., Ltd.

康龙化成（北京）新药技术股份有限公司

 93.67
2 Vendor 2 87.67
3 Vendor 3 74.33

3. Public Notice & Contact

Public notice period: June 13, 2025 - June 17, 2025.

4. Objections and Complaints

If a bidder or any other interested party has an objection to the bid evaluation results, they must submit a written objection to the tendering entity during the public notice period. The tendering entity will provide a written response within three (3) days of receiving the objection. Bidding activities will be suspended until a response is issued.

If the bidder or interested party remains dissatisfied with the tendering entity’s response, they may file a formal complaint with the relevant industry regulatory authority or public resource trading supervision agency within ten (10) days of receiving the response. The complaint must include the tendering entity’s reply and a written complaint letter.

Contact Information

Ms May Chen (Procurement Manager)

may.chen@bayvaxbio.com

Closed Tender: Preclinical Toxicity Study (Ref: TOX-2025-001)
Project Title Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine
Reference No TOX-2025-001
Budget Not exceeding HKD 1,500,000
Deadline June 6, 2025

1. Background

We seek qualified Contract Research Organizations (CROs) to conduct an IND-enabling toxicity study for a peptide-based neoantigen cancer vaccine. This study is critical to support Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE) in China and the U.S. Food and Drug Administration (FDA).

2. Scope of Work

  • Toxicology Studies: Repeat-Dose Toxicity, Immunogenicity, and Immunotoxicity Assessment.
  • Regulatory Compliance: FDA eCTD requirements and CDE guidelines.

3. Eligibility Criteria

  • Experience: Proven track record in oncology vaccine preclinical studies
  • Regulatory Expertise: Prior successful IND submissions to FDA and CDE
  • Facilities: AAALAC-accredited laboratories with GLP certification

4. Evaluation Criteria

Citerion Weight
Scientific & Technical Merit 40%
Regulatory Compliance 30%
Cost-Effectiveness 20%
Past Performance 10%

5. Timeline

  • Submission Deadline: June 6, 2025
  • Contract Award: June 13, 2025
  • Study Start: July 1, 2025
  • Final Report Delivery: May 15, 2026

Contact Information

Ms May Chen (Procurement Manager)

may.chen@bayvaxbio.com

Note: Proposals exceeding the budget cap will be disqualified. Inquiries must be submitted by June 10, 2025.

Our Ecosystem

Uniting with pioneering partners to accelerate breakthrough therapies.

Incubators


Investors


Private Investor

Research poster

100%